Ultomiris for Paroxysmal Nocturnal Hemoglobinuria

News
Article

Ultomiris

ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)

Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria

Dosage: intravenous infusion only

  • 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance

  • 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance

  • 100kg ≤  X – 3,000mg leading, 3,600 maintenance

Contraindications: patients with unresolved Neisseria Meningitidis infection.

 

​Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.